Tempus Surpasses 500 Research Publications
Tempus AI (NASDAQ: TEM) has achieved a significant milestone with over 500 research publications in eight years, emphasizing its commitment to scientific rigor and advancing precision medicine. The company's research portfolio includes 143 peer-reviewed articles, 291 poster presentations, and 31 oral presentations at major scientific conferences. Key forums include the ASCO Annual Meeting and SABCS. Their research supports the clinical validation of Tempus tests, such as HRD and TO, and showcases advancements in genomic sequencing and molecular profiling. CEO Eric Lefkofsky and Senior Strategic Advisor Norman E. Sharpless highlight the importance of Tempus' contributions to biomedical research and clinical care advancements.
- Tempus AI has published over 500 research works, including 143 peer-reviewed articles.
- The company presented 291 posters and 31 oral presentations at major scientific conferences.
- Research validates Tempus' diagnostic tests like HRD and TO, enhancing clinical care.
- None.
- 143 peer-reviewed articles, of which 106 were Tempus-authored;
- 291 poster presentations based on clinical and research data presented at major scientific conferences; and
- 31 oral presentations at scientific meetings such as the American Society of Clinical Oncology (ASCO) Annual Meeting, San Antonio Breast Cancer Symposium (SABCS), Society for Immunotherapy of Cancer (SITC) Annual Meeting, and American Heart Association’s Scientific Sessions.
“We have always prioritized scientific rigor around our offerings, and we are proud of the high quality research we’ve produced in the last eight years,” said Eric Lefkofsky, Founder and CEO of Tempus. “We have always believed that our solutions can meaningfully advance clinical care for patients, and the breadth and depth of our research truly demonstrates that.”
In addition to the clinical validation of each Tempus test, including its algorithmic diagnostics like HRD and TO, Tempus has published landmark research around the clinical utility of its comprehensive portfolio of molecular profiling tests. Tempus has an increasingly large presence at the top oncology conferences around the world, including ASCO Annual Meeting and American Association for Cancer Research (AACR) Annual Meeting, presenting almost 280 authored presentations that showcase the ways in which Tempus’ genomic sequencing tests and multimodal database are advancing both clinical care for patients, as well as the research and development of the next generation of cancer treatments.
“Having spent a lifetime advancing biomedical research, it is imperative for organizations like Tempus to contribute their findings back to the medical community,” said Norman E. Sharpless, MD, former Director of the National Cancer Institute and Senior Strategic Advisor at Tempus. “Researchers need data in order to advance findings, and it's going to take the collective capabilities of everyone in the ecosystem to eradicate diseases like cancer.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of Tempus’ research and publications; the contributions of Tempus’ research and findings to the larger scientific community and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Final Prospectus filed with the Securities and Exchange Commission (“SEC”) on June 17, 2024, pursuant to Rule 424(b)(4) under the Securities Act, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710634642/en/
Erin Carron
media@tempus.com
Source: Tempus AI, Inc.
FAQ
What milestone did Tempus AI (NASDAQ: TEM) recently achieve?
How many peer-reviewed articles has Tempus AI published?
What types of research presentations has Tempus AI conducted at scientific conferences?
Which diagnostic tests by Tempus AI are clinically validated through their research?
Which major scientific conferences feature Tempus AI's research?
What does Tempus AI's research portfolio include?
